1 证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2023-002 | 投资者关系活 | 分析师会议 □特定对象调研 □ | | | | | | --- | --- | --- | --- | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | | | | | □ 新闻发布会 □ 路演活动 | | | | | | | □ 现场参观 | | | | | | | 其他 （请文字说明其他活动内容） □ | | | | | | 参与单位名称 | 投资者网上提问 | | | | | | 及人员姓名 | | | | | | | 时间 | 年 2023 (周五) | 5 | 月 | 12 | 日 | | 地点 | 公 司 通 过 全 景 网 " 投 资 者 关 系 互 动 平 台 " | | | | | | | （https://ir.p5w.net）采用网络远程的方式召开业绩 | | | | | | | 说明会 | | | | | | 上市公司接待 | 1、董事长吴海明 | | | | | | 人员姓名 | 2、副董事长、总经理柴军 | | | ...

证券代码：000705 证券简称：浙江震元 公告编号：2023-019 浙江震元股份有限公司 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日 活动暨 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江震元股份有限公司（以 下简称"公司"）将参加由浙江证监局、浙江省上市公司协会与深圳 市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投资者 集体接待日活动" 暨公司 2022 年度业绩说明会，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下 载全景路演APP,参与本次互动交流，活动时间为2023年5月12日（周 五）15:00-17:00。届时公司董事长吴海明先生；副董事长、总经理 柴军先生（代行财务总监）；董事会秘书周黔莉女士将在线，就公司 2022年度业绩、公司治理、发展战略、 经营状况等投资者关心的问 题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 为 ...

证券代码：000705 证券简称：浙江震元 公告编号：2023-019 浙江震元股份有限公司 （问题征集专题页面二维码） 特此公告。 浙江震元股份有限公司董事会 2023 年 5 月 8 日 关于参加浙江辖区上市公司 2023 年投资者网上集体接待日 活动暨 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，浙江震元股份有限公司（以 下简称"公司"）将参加由浙江证监局、浙江省上市公司协会与深圳 市全景网络有限公司联合举办的"2023 年浙江辖区上市公司投资者 集体接待日活动" 暨公司 2022 年度业绩说明会，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下 载全景路演APP,参与本次互动交流，活动时间为2023年5月12日（周 五）15:00-17:00。届时公司董事长吴海明先生；副董事长、总经理 柴军先生（代行财务总监）；董事会秘书周黔莉女士将在线，就公司 2022年度业绩、公司治 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,098,106,955.60, representing a 13.88% increase compared to CNY 964,264,259.83 in the same period last year[8]. - Net profit attributable to shareholders was CNY 18,564,267.15, up 22.32% from CNY 15,176,300.98 year-on-year[8]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which reached CNY 18,141,480.93, a 43.39% increase from CNY 12,651,652.58 in the previous year[8]. - Operating profit for Q1 2023 was RMB 26,499,583.72, up 37.9% from RMB 19,207,955.22 year-on-year[22]. - Total comprehensive income for Q1 2023 was RMB 18,878,980.49, compared to RMB 9,921,713.67 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 4,328,543.90, a 102.96% increase from a negative cash flow of CNY -146,188,505.11 in the previous year[8]. - The company reported a net cash flow from operating activities of RMB 4,328,543.90, a significant improvement from a negative RMB 146,188,505.11 in the previous year[24]. - Cash and cash equivalents were RMB 418,758,680.05, compared to RMB 453,484,094.17 at the beginning of the quarter[21]. - Cash and cash equivalents at the end of Q1 2023 totaled RMB 398,480,777.79, compared to RMB 239,534,691.49 at the end of Q1 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,180,750,392.19, a decrease of 1.49% from CNY 3,228,804,787.20 at the end of the previous year[8]. - Current assets totaled RMB 2,066,776,798.13, down from RMB 2,109,682,646.88 at the start of the quarter[21]. - Total liabilities were RMB 1,215,943,912.23, down from RMB 1,282,876,202.82[21]. - Current liabilities totaled RMB 1,030,132,070.51, a decrease from RMB 1,094,951,501.72[21]. Shareholder Equity - The net assets attributable to shareholders increased to CNY 1,940,045,142.50, marking a 0.91% rise from CNY 1,922,470,592.26 at the end of the last year[8]. - The company's equity attributable to shareholders was RMB 1,940,045,142.50, slightly up from RMB 1,922,470,592.26[21]. - The company reported a net profit of RMB 838,807,368.57 in retained earnings, compared to RMB 820,243,101.42 at the beginning of the quarter[21]. Earnings Per Share - The basic earnings per share rose to CNY 0.0556, reflecting a 22.47% increase compared to CNY 0.0454 in the same period last year[8]. - Basic and diluted earnings per share for Q1 2023 were both RMB 0.0556, an increase from RMB 0.0454 in the same period last year[22]. Other Financial Metrics - The weighted average return on equity improved to 0.96%, up from 0.82% in the previous year, an increase of 0.14 percentage points[8]. - Research and development expenses for Q1 2023 were RMB 8,840,762.38, slightly up from RMB 8,045,330.27 in the same period last year[22]. - The company experienced a decrease in other comprehensive income, with a net amount of RMB -988,632.00 compared to RMB -5,746,211.00 in Q1 2022[22]. - The report for the first quarter of 2023 was not audited[20]. Investment Income - Investment income dropped significantly by 97.52% to CNY 49,817.82 compared to CNY 2,009,102.68 in the previous year, primarily due to the expiration of financial products[12]. Contract Liabilities - The company experienced a 60.49% decrease in contract liabilities, down to CNY 11,895,987.12 from CNY 30,111,854.29[12].

浙江震元股份有限公司2022年年度报告 浙江震元股份有限公司 2022 年年度报告 ...

证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2014-005 | --- | --- | --- | |------------------|--------------------------|----------------------------------------------------------| | | | | | 投资者关系活动类 | □ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | √ | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位名称 | | 东方证券、华夏基金、国泰基金、大成基金、泰信基金、银河 | | | | 基金、中银基金、汇添富基金、交银施罗德基金、金元惠理 | | | | 基金、圆信永丰基金、海通证券资管、平安资产管理、国泰 | | | | 君安证券资管、财通证券、国金证券、韩国投资、尚雅投资、 | | | | 北京鸿道投资、上海同犇投资、深圳鼎诺投资等共计 25 人 | | 时间 | 2014 年 7 月 31 | 日星 ...

Group 1: Product Launch and Sales Strategy - The company has obtained new drug certification and registration for adenosylmethionine, aiming for a quick market acceptance due to its familiarity among doctors [1] - Future sales strategy for adenosylmethionine will focus on agency-based marketing [2] - Sales of methadone series products showed significant year-on-year growth, but further academic promotion and bidding work are necessary for increased volume [2] Group 2: Sales Performance and Challenges - In the first half of the year, the company achieved sales of 80.93 million yuan for formulations, a slight decline attributed to the new GMP certification process for injection products [3] - Raw material sales reached 86.37 million yuan, showing a decrease due to price fluctuations in upstream raw materials [3] - The company’s traditional Chinese medicine (TCM) sales reached 67.11 million yuan, with a year-on-year increase, despite challenges from GMP re-certification [4] Group 3: Future Development and Market Expansion - The company plans to enhance the quality of TCM products in response to increasing consumer demands and regulatory standards [4] - The health industry development strategy includes expanding into maternal and infant care services, oral health services, and health management [5] - The company is actively seeking suitable acquisition targets related to its main business, such as traditional Chinese medicine production enterprises [5] Group 4: Research and Development - The company’s research center focuses on microbial fermentation and synthetic pharmaceutical engineering, with plans to develop new drugs targeting antifungal and digestive system treatments [5] - Ongoing research projects are progressing as planned, with a focus on leveraging various R&D resources [5]

编号：2015-002 证券代码：000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 | --- | --- | |------------------------|-----------------------------------------------| | | | | 投 资 者 关 系 活 | 特定对象调研 □分析师会议 | | 动类别 | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | 现场参观 □其他（请文字说明其他活动内容） | | 参与单位名称 | 博时基金、银河证券 | | 时间 | 2015 年 5 月 13 日星期三 | | 地点 | 公司会议室 | | 上 市 公 司 接 待 人员 | 董事会秘书及证券事务代表 | | 投 资 者 关 系 活 | 1 、介绍下公司零售连锁的发展情况，其中中医 | | 动 主 要 内 容 介 | 坐诊的有多少家，未来规划？ | | 绍 | 目前零售连锁门店共有 70 多家，近年来，零 | | | 售连锁门店数量没有大的变化，主要注重门店规模 | | | 的提升，调整和增设中医坐诊门店，现在共有十余 | ...